MedPath

Early Detection of Clinical Deterioration in Patients With COVID-19 Using Machine Learning

Conditions
Covid19
Registration Number
NCT04828915
Lead Sponsor
University Hospital Tuebingen
Brief Summary

The aim of this study is to use artificial intelligence in the form of machine learning analysing vital signs as well as symptoms of patients suffering from Covid19 to identify predictors of disease progression and severe course of disease.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
1000
Inclusion Criteria
  • Written informed consent
  • Age >= 18 years
  • Detection of SARS-CoV2 within the past 5 days
Exclusion Criteria
  • Inability to measure vital parameters and document symptoms

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Probability of Participants for Hospitalisation or Fatal OutcomeDetection of severe acute respiratory syndrome- Corona Virus 2 (SARS-CoV2) to recovery, hospitalisation or fatal outcome up to 5 weeks
Secondary Outcome Measures
NameTimeMethod
Probability of Participants for Intensive Care Unit AdmissionDetection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks
Prediction of persisting health impairment by using standardized questionnairesDetection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks
Detection of symptoms, vital parameters and comorbidities predicting clinical courseDetection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks
Influence of different virus variants on the course of disease/ clinical outcomeDetection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks
Influence of SARS-CoV2 vaccination (yes/no) on the course of disease/ clinical outcomeDetection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks
Probability of Participants for hospitalisationDetection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks
Probability of Participants for Fatal OutcomeDetection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks
Evaluation of parameters (symptoms, vital parameters, comorbidities) according to their potential of clinical course predictionsDetection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks
Influence of different SARS-CoV2 vaccines on the course of disease/ clinical outcomeDetection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks
Influence of size of training data setDetection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks
Influence of viral load on the course of disease/ clinical outcomeDetection of SARS-CoV2 to recovery, hospitalisation or fatal outcome up to 5 weeks

Trial Locations

Locations (1)

University Hospital of Tuebingen

🇩🇪

Tuebingen, Germany

University Hospital of Tuebingen
🇩🇪Tuebingen, Germany
Annika Buchholz, Ph.D.
Contact
+4915151819576
annika.buchholz@tuebingen.mpg.de
Juergen Hetzel, M.D.
Principal Investigator
Bijoy N Atique, M.D.
Sub Investigator
Maik Haentschel, M.D.
Sub Investigator
© Copyright 2025. All Rights Reserved by MedPath